Bariatric and Metabolic Surgery

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

In Brief

Metabolic and bariatric surgery is the most effective and durable established treatment for severe obesity, producing larger and more extensively documented long-term weight loss than lifestyle change and, on average, than currently established medication approaches. It is also genuinely a metabolic treatment: these operations improve type 2 diabetes faster and more fully than the weight loss alone would predict, working through changes in gut hormones, bile-acid signaling, and other pathways rather than by shrinking the stomach alone.

Surgery is not one intervention. Sleeve gastrectomy, gastric bypass, and the more extensive operations differ substantially in weight loss, diabetes effect, reflux, and lifelong nutritional burden, and choosing among them is one of the central decisions this article tries to make legible. That choice is a genuine trade: greater average efficacy and durability in exchange for operative risk, durable changes to the anatomy, lifelong monitoring, and procedure-specific complications.

The evidence is strong but uneven. Randomized trials establish the effects on weight, diabetes, and blood pressure; large long-term studies associate surgery with fewer heart attacks and strokes and longer life — an association that is consistent but not proven by randomized trials. In experienced centers, perioperative mortality is low, though individual risk varies. Set against the benefits are real costs: lifelong vitamin supplementation and monitoring, and, for a minority, an increased risk of alcohol use disorder and of self-harm.

Why It Is Called Metabolic Surgery

The older assumption was mechanical: make the stomach smaller, and a person eats less. Restriction is part of the story, but not the whole explanation. The observation that reshaped the field is that type 2 diabetes often begins to improve within days of surgery — particularly after gastric bypass — before much weight has been lost.² The severe calorie restriction that follows surgery contributes to that early change by rapidly improving the liver’s handling of glucose. But surgery also alters gut-hormone signaling, nutrient flow, bile-acid signaling, and gastric emptying in ways that appear to produce metabolic effects beyond weight loss alone, which is why diabetes can improve out of proportion to the weight lost.²

The reasons are only partly understood, and no single mechanism accounts for them. Rerouting or reshaping the gut changes how and where food is sensed, shifting several systems at once: the release of gut hormones such as GLP-1 and PYY (the hormones the medications in Article 5 mimic), bile-acid signaling, gastric emptying, nerve signaling between gut and brain, and the gut microbiome — alongside reduced calorie intake and the effects of weight loss itself.² Changes in gut bacteria are associated with these operations and may also contribute, though their causal role in humans is not settled.² The relative importance of each pathway differs by procedure and by which outcome is measured. The practical point is that these operations work partly through physiology, not willpower — which is why the field now speaks of metabolic surgery.

This is the last of the three treatment articles. Articles 5 and 6 covered medications; Article 8 explains why body weight is so strongly defended regardless of how it is lost.

The Main Procedures

Almost all bariatric surgery today is performed with minimally invasive techniques — laparoscopic or robotic, through small incisions. Two operations account for the large majority.

Sleeve gastrectomy is now the most commonly performed procedure.¹⁸ About 80% of the stomach is permanently removed, leaving a narrow tube. It involves no rerouting of the intestine and is technically simpler than bypass, while still producing substantial hormonal change. Because roughly four-fifths of the stomach is removed, it is not reversible. Its main drawback is reflux: the sleeve can cause new acid reflux or worsen existing reflux, so significant pre-existing reflux or a diagnosis of Barrett’s esophagus can weigh against it.⁴

Roux-en-Y gastric bypass creates a small stomach pouch and connects it to a lower segment of the small intestine. Food travels down this new limb while digestive juices from the bypassed stomach and upper intestine travel separately, the two streams mixing further downstream — the “Y” the procedure is named for. Bypass usually improves rather than worsens reflux, which is why it is often preferred when significant reflux is present; its trade-offs are a more complex operation and higher long-term risks of certain nutritional deficiencies and of internal hernia.³,⁴

Beyond these two, the adjustable gastric band — once common — has been largely abandoned because its long-term weight loss was smaller and less durable and its reoperation rate high. Two more extensive operations, biliopancreatic diversion with duodenal switch (BPD-DS) and the newer single-anastomosis duodeno-ileal bypass (SADI-S), are not the same procedure: they differ in anatomy, in the number of surgical connections, and in how mature their long-term evidence is, with SADI-S the newer and less established of the two. Both add a substantial malabsorptive component and generally produce the greatest average weight loss and metabolic effect,¹ at the cost of the highest nutritional risk, including protein-energy malnutrition.¹⁴ They are generally reserved for selected patients with very high BMI or severe metabolic disease, or as revisional surgery.¹

A separate category — endoscopic therapies such as the intragastric balloon and endoscopic sleeve gastroplasty — is performed through the mouth without surgical incisions and is outside the scope of this article.

Choosing the Operation: Sleeve, Bypass, or More?

For most people the real decision is between sleeve gastrectomy and gastric bypass, and understanding how that decision is reasoned through matters more than any single statistic. Averaged across the literature, bypass tends to produce somewhat greater weight loss and diabetes improvement than sleeve — but the 10-year randomized comparison (SLEEVEPASS) found the two closer than observational data suggest, with more reflux after sleeve and better blood-pressure improvement after bypass.³,⁴ For many patients, the differences in average weight and diabetes outcomes are not large enough to decide the choice by themselves, so reflux, nutritional burden, medication needs, anatomy, and individual priorities often become decisive.

Several considerations legitimately push toward one operation:

• Significant reflux or Barrett’s esophagus usually favors bypass, which tends to improve reflux, while sleeve can worsen or cause it.⁴
• Severe diabetes, where a stronger metabolic effect is sought, may favor bypass or, in selected cases, a duodenal-switch-family operation.¹
• Concern about nutritional burden favors sleeve, which generally carries the lighter burden — though it still requires lifelong supplementation and monitoring.¹⁴
• Regular need for NSAIDs matters, because these drugs raise the risk of ulcers where a bypass pouch meets the intestine.¹⁴
• Smoking or nicotine use is not a minor administrative note; it meaningfully raises ulcer and healing risk, particularly around bypass, and is important to stop before surgery.
• Very high BMI can shift procedure selection, and staged approaches are sometimes considered.¹
• A history of kidney stones deserves discussion, since some procedures raise stone risk.¹⁴
• Certain chronically taken medications with narrow absorption windows can behave differently after rerouting, which may influence the choice.¹⁴
• The ability to sustain lifelong supplementation and follow-up is a genuine determinant of which operation is suitable, not paperwork — the more malabsorptive the procedure, the more this matters.¹⁴

The table below compares the operations on the questions people actually ask. It uses directional language rather than precise percentages, because weight-loss figures vary with the metric used, the follow-up time, and the population studied.

This is a map of the trade-offs, not a formula — the point is to make the decision, with a surgical team, an informed one.

Who Is a Candidate

For thirty years, eligibility followed criteria set by a 1991 National Institutes of Health panel: a body mass index (BMI) of 40 or above, or 35 or above with a serious weight-related condition. In 2022, the two major surgical societies updated those thresholds.¹

Important: guideline eligibility and insurance coverage are not the same thing. Many payers still apply older criteria or require documented attempts at nonsurgical treatment, so what a guideline recommends and what a given plan will cover can differ.

Meeting a threshold does not by itself make surgery the right choice. Candidacy also weighs disease burden, prior treatment, operative risk, the ability to attend long-term follow-up and take supplements, nutritional status, active substance use, and psychological readiness. That last phrase should not be a black box. The multidisciplinary evaluation — surgeon, dietitian, and often a psychologist — is not a test of moral worth or a search for reasons to refuse someone. It looks for specific, addressable things: active substance use, untreated or unstable severe psychiatric illness, suicidality, disordered eating that needs management, whether a person understands the procedure, whether they can engage with postoperative nutrition and follow-up, and practical or social barriers to doing so. That same list points to honest reasons a person and their team might choose to wait rather than operate now — active smoking that has not yet been stopped, untreated alcohol or substance use, unstable psychiatric illness, or the expectation that surgery will do the work of changed eating and lifelong follow-up on its own. Waiting to address these is not a rejection; it is often what makes surgery more likely to succeed.

Two points often surprise people: chronological age alone is not an absolute barrier — frailty, organ function, operative risk, and goals matter more than a number — and current tobacco use is important to address beforehand, because smoking raises both perioperative risk and the later risk of ulcers. (Surgery in adolescents is a separate, specialized topic.) Surgery is a legitimate treatment for a chronic disease, and one that remains substantially underused relative to the number of people who would qualify.¹

What the Evidence Shows

Bariatric surgery is among the most thoroughly studied interventions in obesity medicine, with follow-up in some studies beyond 20 years. Its evidence is not uniform in strength: randomized trials establish the effects on weight, blood sugar, blood pressure, and other risk factors, while the links to fewer cardiovascular events and longer life come from large but non-randomized studies — powerful and consistent, yet observational.

Weight. In the STAMPEDE randomized trial — conducted in people with obesity and uncontrolled type 2 diabetes, not a general population — patients lost about 23% of their total body weight five years after gastric bypass and about 19% after sleeve gastrectomy, against about 5% with intensive medical therapy.³ The typical pattern is rapid loss to a low point (“nadir”) in the first one to two years, some regain thereafter, then a long plateau that retains much of the loss — a study following gastric-bypass patients for 12 years found substantial weight loss maintained well past the point at which diet-induced loss usually reverses.¹²

Type 2 diabetes. In STAMPEDE, far more surgical than medical patients reached target blood sugar and reduced or stopped diabetes medications, including insulin.³ A separate trial found durable diabetes remission in a substantial share of surgical patients at 10 years — a result medication alone did not match.¹⁰ Remission has a specific meaning — by consensus definition, an HbA1c below 6.5% sustained for at least three months without glucose-lowering medication — and it is not the same as cure: diabetes can relapse years later, particularly with weight regain, and even in remission its complications require continued surveillance of the eyes, kidneys, heart, and blood sugar, guided by prior disease burden.¹⁹ A period of remission may still provide meaningful benefit by reducing cumulative exposure to high blood sugar, even if diabetes later returns.¹⁷ Surgery is also associated with fewer of the downstream complications of diabetes, including damage to the small vessels of the eyes and kidneys.⁸ Several factors predict remission, but the duration of diabetes before surgery matters especially — the shorter it has been present, the better the odds.

Blood pressure. High blood pressure improves as well, and here the evidence is randomized. In the GATEWAY trial, adding gastric bypass to medical therapy produced far higher rates of substantial reduction in blood-pressure medication at one year — about 84%, against roughly 13% with medication alone — while maintaining blood-pressure control.²¹ The benefit proved durable: at five years, about half of the surgical patients achieved hypertension remission — blood pressure controlled without any antihypertensive medication — compared with about 2% of those treated with medication alone.²⁷

Cardiovascular events and survival. A 2022 meta-analysis of 39 studies linked surgery to roughly halved all-cause and cardiovascular mortality, along with fewer heart attacks, strokes, heart-failure events, and kidney complications.²⁰ The Swedish Obese Subjects study — the largest and longest, following about 2,000 surgical patients against matched controls — found surgery associated with roughly 29% lower overall mortality, fewer cardiovascular events, and longer life expectancy; a large matched analysis in people with diabetes reached similar conclusions for major cardiovascular events.⁶,⁷,⁹,¹³,¹¹ These findings are consistent across many independent datasets. But they are non-randomized: despite careful matching, they cannot fully exclude that the people who had surgery differed from those who did not — in baseline health, access to care, socioeconomic circumstances, or other unmeasured ways — so residual confounding, not motivation alone, is the limitation. The effect on weight, diabetes, and blood pressure is established by randomized trials; the effect on heart attacks, strokes, and death is a strong, consistent association that randomized trials have not confirmed.

Why should a cardiovascular reader care beyond the event counts? Because surgery may act on cardiovascular risk through several pathways at once — substantial weight loss, better blood-sugar control, lower blood pressure, improved sleep apnea, less metabolic liver disease, greater physical capacity, and lower kidney risk. That does not prove any single pathway causes the observed reduction in events, but it explains why the cardiovascular question is broader than weight alone.²⁰ One caution belongs alongside it: surgery can substantially improve cardiometabolic risk, but it does not erase established coronary disease or remove the need to manage blood pressure, cholesterol, diabetes, smoking, sleep apnea, and activity. Improved weight and metabolic health can reduce medication needs, but treatments prescribed for established cardiovascular disease should not be stopped simply because weight, blood pressure, blood sugar, or cholesterol values have improved.

Surgery also improves several other obesity-related conditions relevant to the heart. It produces long-term resolution of metabolic dysfunction-associated steatotic liver disease (MASLD) — including its inflammatory form, MASH (formerly NASH) — in a large share of patients.²⁴ It often improves obstructive sleep apnea and can bring remission in some, though persistent disease is common enough that CPAP or other treatment should not be stopped without reassessment.²⁵ And it improves quality of life and physical function — mobility, pain, and daily activity — which matter as much to most people as the laboratory numbers.²⁶

What the Numbers Mean — and What They Cannot Predict

Every figure in the evidence above describes a group, not a guarantee. Around each average sits a wide range: two people with the same operation can have very different results, and a minority lose little or regain substantially. Procedure, starting weight, how long diabetes has been present, age, biology, and how closely a person stays engaged with follow-up all shape the outcome.

Success is also broader than the averages suggest. Beyond weight loss, it can mean improvement or remission of diabetes, fewer medications, better blood pressure, improved mobility and exercise capacity, better sleep apnea and liver disease, preserved muscle, and better quality of life. Judging surgery only by the number on the scale misses many of the outcomes that matter most — and some regain, later, does not by itself mean the surgery failed.

The Risks and Trade-offs

The risks deserve as much weight as the benefits, and it helps to sort them by when they arise.

Early complications (around the operation). In contemporary practice, perioperative death is uncommon. A large multinational registry of primary bariatric operations performed during 2020, in the COVID-19 pandemic, reported a 30-day mortality of about 0.14% and an overall 30-day complication rate of about 6.8%,³⁰ consistent with a recent meta-analysis putting 30-day mortality below 0.5%.²⁰ (The older landmark LABS study, still widely cited, found a composite of major early problems — blood clots, reoperation, prolonged hospitalization — in about 4%.⁵) Early complications include a leak (leakage of stomach or intestinal contents from a staple or surgical connection), bleeding, blood clots, and dehydration. It helps to distinguish death, which is rare, from serious complications, readmission, and reoperation, which are more common and worth asking a program about directly. Risk is not identical across operations or people: it is higher with more advanced disease, prior blood clots, or sleep apnea, and bypass carries a somewhat higher early-complication rate than sleeve.⁵

Long-term complications. Because these operations change how the gut absorbs nutrients, they create lifelong requirements, and the burden rises with how malabsorptive the procedure is: sleeve can cause deficiencies, bypass more, and BPD-DS and SADI-S substantially more, including protein-energy malnutrition.¹⁴ Common issues include iron deficiency and anemia; low vitamin B12 and folate; and low calcium and vitamin D. Bone loss can continue after the phase of rapid weight loss, particularly after procedures that alter intestinal absorption, so long-term care may include attention not only to calcium and vitamin D but also to bone-density assessment when clinically appropriate.¹⁴ Thiamine (vitamin B1) is a specific danger: persistent or recurrent vomiting after surgery can precipitate severe thiamine deficiency and neurological injury, which is why it warrants prompt medical assessment rather than waiting it out.¹⁴

Other long-term issues can include gallstones (rapid weight loss itself is a cause); marginal ulcers where a bypass pouch meets the intestine (more likely with smoking or NSAID use); internal hernia or bowel obstruction, which can appear years later and become serious; dumping syndrome, in an early form (cramping, nausea, diarrhea, rapid heartbeat soon after eating) and a late form (low blood sugar hours later); post-bariatric hypoglycemia, a distinct and sometimes serious problem separate from dumping; kidney stones, especially after malabsorptive procedures; and reflux, particularly with the sleeve.¹⁴ Surgery can also change how some medications are absorbed, which matters for extended-release drugs and those with a narrow effective range. More broadly, medication lists should be reviewed after surgery rather than simply continued unchanged, because weight loss and improving blood pressure, blood sugar, and kidney function can all change what is needed.¹⁴

Psychological and behavioral trade-offs. On average, mental health and quality of life improve after surgery — yet a smaller group experiences serious harm, and both can be true at once. Two risks stand out. First, alcohol use disorder becomes more common after surgery. The risk is clearest and largest after gastric bypass, after which alcohol can be absorbed much faster and reach substantially higher peak blood-alcohol levels than before surgery, so considerably less alcohol may produce intoxication.²⁸ The effect is not confined to bypass; it typically emerges more than a year — often several years — after surgery, sometimes in someone with no prior history, and those affected face a real risk of severe alcohol-related harm.¹⁵,²³ Second, studies have found higher rates of self-harm and suicide after bariatric surgery than before it and than in matched controls.¹⁶ This association must be read cautiously: people who seek surgery carry a higher baseline burden of psychiatric conditions and trauma than the general population, and comparing the same person before and after surgery also compares different ages and disease stages — so the increase cannot simply be read as surgery causing it. These findings do not mean psychiatric history rules out surgery. They do mean that active substance use, severe or unstable psychiatric illness, and prior self-harm deserve careful assessment, treatment, and a plan for longitudinal support — and in some situations may affect whether or when surgery should proceed.

Warning signs that need urgent attention. A few symptoms warrant prompt contact with the surgical team or emergency care rather than waiting:

• Persistent vomiting or an inability to keep fluids down.
• Severe or escalating abdominal pain.
• Chest pain or shortness of breath.
• Signs of gastrointestinal bleeding.
• Severe symptoms of low blood sugar.

One point is worth carrying for life: after a gastric bypass, severe or intermittent abdominal pain — even years later — can signal an internal hernia; because the diagnosis can be difficult and the problem may present far from the original bariatric center, it is worth telling any treating clinician about the altered anatomy so the possibility is not missed.

Weight Recurrence, Inadequate Response, and Revision

Surgery is not always a single, final event. Two distinct situations arise. Some people regain weight after their low point — modest regain is expected, and more substantial recurrence is not rare — and a separate group never achieves an adequate initial response. Neither is automatically a failure, and both deserve evaluation rather than blame. That evaluation considers anatomy (for example, a stretched pouch), eating patterns, medications that may promote weight gain, and the physiology that defends body weight described in Article 8.

The options depend on the cause. They can include structured behavioral and nutritional support, anti-obesity medication, endoscopic procedures, and, in selected cases, revisional surgery — for example, converting a sleeve to a bypass for severe reflux, or to a more metabolically active operation for inadequate response. On the medication side, GLP-1-based drugs are increasingly used for weight recurrence or inadequate response after surgery, and recent syntheses find they produce meaningful additional weight loss in this setting.²² Revisional surgery is generally more complex than a first operation, and its risks depend heavily on the original anatomy, the reason for revision, and the procedure planned; it should not be pictured as routine maintenance.²⁹ Surgical and medication-based regain also differ conceptually: weight recurrence after surgery reflects anatomy and biology working together over years, whereas regain after stopping a medication reflects removal of an ongoing treatment.

Surgery and Modern Medications

How does surgery compare with the GLP-1 and incretin medications of Article 5? There is no head-to-head randomized trial, and indirect comparison is genuinely difficult: the studies enrolled different populations, ran for different lengths of time, handled treatment discontinuation differently, and measured different things — surgery is assessed as a durable procedure, while a medication’s effect is measured while it is being taken. Precise “one number versus another” claims paper over these differences.

What can be said fairly: among established treatments, surgery — especially the more metabolically powerful procedures — continues to produce the greatest average and most extensively documented long-term weight loss, though the gap has narrowed substantially with the newer incretin-based medications.³,¹² Surgery also does not depend on continuing to take a drug to maintain its biological effect, although it does require lifelong medical and nutritional follow-up, so it is not a one-time healthcare event. The newest medications avoid operative risk and the permanence of altered anatomy and can be stopped, though their effect generally depends on continued use. Recent observational and indirect comparisons have begun to weigh surgery against GLP-1-based therapy for long-term outcomes, but these are non-randomized and cannot establish that one causes better outcomes than the other.

Increasingly, the two are studied and used together in selected situations rather than as rivals — a medication before surgery to reduce weight or optimize metabolic status, instead of surgery for those who cannot or prefer not to operate, or after surgery for weight recurrence or inadequate response.²² A growing number of people also arrive at surgery already taking a GLP-1-based medication, and how best to continue, pause, or resume these drugs around an operation is an area of active study rather than settled practice. As Article 8 explains, the body defends its weight however that weight is lost, which is the deeper reason long-term treatment of some kind — surgical, medical, or both — is usually necessary.

Recovery and Long-Term Life

Recovery from a minimally invasive procedure is often quicker than people expect, though it varies by operation, patient, and program — commonly a one- to two-night hospital stay, with shorter and longer courses both occurring. Return to activity is not a single milestone: desk work usually resumes within a week or two, while lifting and strenuous exercise are restricted longer. Eating advances in stages that differ by program, typically from liquids to purées to solid food over several weeks. Portions are much smaller afterward, though capacity and tolerance change over the first year and beyond rather than staying fixed forever. Protein is prioritized deliberately, and staying hydrated is one of the most common practical challenges early on.

Muscle deserves particular attention. Large weight loss is not purely fat loss; lean mass is lost too. Preserving strength, mobility, and balance — not simply minimizing the number on the scale — is a central goal, and it matters most for older adults, in whom lost muscle can translate into lost independence. Adequate protein and regular resistance activity are the main tools for protecting lean mass, and they matter throughout life after surgery, not only in the first months. This is where surgery connects to the movement and nutrition foundations covered elsewhere in this series.

The routine matters more than the recovery. Follow-up is most intensive in the first year and continues indefinitely, with blood tests tailored to the procedure and the person. In practical terms, long-term monitoring covers blood count and iron; vitamin B12 and folate; vitamin D, calcium, and bone health; micronutrients specific to the procedure; protein and overall nutritional status; diabetes and cardiometabolic markers; and mental health and substance use where relevant.¹⁴ An uncomfortable reality: many people drift away from bariatric follow-up over the years — because they feel well, move, change insurance, or lose access to their original program. Nutritional and metabolic problems can surface years later, which is why long-term laboratory surveillance should continue even after weight has stabilized and everything feels fine.

Some consequences are practical rather than medical — loose or excess skin is common after large weight loss, and major changes in body and health can affect relationships, eating patterns, social life, and self-image, sometimes because the body changes faster than a person’s sense of identity does. None of this is a mark against surgery; it is what treating a chronic disease looks like.

Questions to Ask a Bariatric Program

The decision is easier to make well with the right questions. Worth asking:

• Which procedures do you perform most often, and why might one suit my combination of reflux, diabetes, BMI, medications, and nutritional risk?
• What are your program’s leak, readmission, reoperation, and 30-day mortality rates?
• How do you handle urgent problems after hours, and what should I do in an emergency?
• What long-term laboratory monitoring do you require, and who follows my nutrition and deficiencies years later?
• What is your approach to weight recurrence, and when do you use anti-obesity medications after surgery?
• How do you screen for and support alcohol and mental-health concerns before and after surgery?
• If I develop severe abdominal pain years later and can’t reach you, what should I tell an emergency physician about my altered anatomy?
• Which medications should I avoid or take differently after this procedure?
• How many of the specific operation you’re recommending does your program perform each year?
• Years from now, who owns my long-term follow-up — your program, my primary-care clinician, or both?
• What happens if a move, insurance change, or distance makes long-term follow-up difficult?

Pregnancy and Reproductive Considerations

For people who can become pregnant, surgery has important reproductive implications. Weight loss often improves fertility — including in those with polycystic ovary syndrome or irregular ovulation — so pregnancy can happen sooner and more easily than expected, even though surgery is not a treatment for infertility. Many guidelines and expert groups recommend avoiding conception during the phase of rapid weight loss — commonly for at least 12 to 18 months after surgery, though recommendations vary — so timing is best individualized with the bariatric and obstetric teams.¹⁴ Reliable contraception therefore matters, and because absorption of oral contraceptives may be reduced after some procedures, non-oral methods are worth discussing. During any pregnancy after surgery, nutritional monitoring before, during, and after — coordinated among the bariatric team, obstetric care, and a dietitian — helps prevent the deficiencies that can affect mother and baby.¹⁴

Clinical Bottom Line

For people with severe obesity, metabolic and bariatric surgery remains the most effective and durable established treatment, and genuinely a metabolic one — improving diabetes and other risk factors through physiology, not by restricting the stomach alone. Randomized trials establish its effects on weight, diabetes, and blood pressure; its links to fewer heart attacks and strokes and to longer life are strong but observational, and it does not end the need to manage established cardiovascular risk. Those benefits come with real, lasting costs: a small operative risk, lifelong supplementation and monitoring, procedure-specific complications, and — for a minority — a higher risk of alcohol use disorder and self-harm. For some people the benefits clearly outweigh the burdens, and surgery remains the benchmark for the magnitude and durability of weight loss in severe obesity. But which operation fits, and whether to operate at all, is an individual decision best made with a multidisciplinary team.

What Comes Next

Whether weight is lost through lifestyle change, medication, or surgery, the body responds in ways that make it hard to keep off. Article 8 explains the biology of weight regain — why hunger and metabolism shift after weight loss, what tends to happen when treatment stops, and why understanding this is essential to setting realistic expectations rather than assigning blame.

Key Terms

Bariatric surgery / metabolic surgery: Operations on the stomach and intestine that produce weight loss and improve metabolic conditions such as type 2 diabetes; “metabolic” emphasizes the benefits that exceed what weight loss alone would predict.

Sleeve gastrectomy: The most common operation, permanently removing about 80% of the stomach to leave a narrow tube; the intestine is not rerouted.

Roux-en-Y gastric bypass: An operation creating a small stomach pouch connected to a lower part of the small intestine, bypassing most of the stomach and upper intestine.

BPD-DS and SADI-S: Two distinct duodenal-switch-family operations that combine a sleeve with substantial intestinal rerouting. They generally produce the greatest average weight and metabolic effects and carry the greatest nutritional burden; long-term evidence is more mature for BPD-DS than for SADI-S.

Remission (of diabetes): By consensus definition, an HbA1c below 6.5% sustained for at least three months without glucose-lowering medication. It is not a cure — relapse can occur, and complication monitoring continues.

Malabsorption: Reduced absorption of nutrients from food, a deliberate effect of some procedures that drives the need for lifelong supplementation.

Dumping syndrome: Symptoms triggered by food reaching the intestine too quickly — an early form (cramping, nausea, diarrhea, rapid heartbeat) and a late form (low blood sugar hours after eating).

Revisional surgery: A second operation to address complications, inadequate response, or weight recurrence — for example, converting a sleeve to a bypass; generally more complex than a first operation.

Non-randomized (observational) study: A study comparing people who did and did not receive a treatment without random assignment; it can show strong associations but cannot prove cause the way a randomized trial can.

References

1. Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2022;18(12):1345–1356. https://doi.org/10.1016/j.soard.2022.08.013
2. Batterham RL, Cummings DE. Mechanisms of diabetes improvement following bariatric/metabolic surgery. Diabetes Care. 2016;39(6):893–901. https://doi.org/10.2337/dc16-0145
3. Schauer PR, Bhatt DL, Kirwan JP, et al; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes — 5-year outcomes. N Engl J Med. 2017;376(7):641–651. https://doi.org/10.1056/NEJMoa1600869
4. Salminen P, Grönroos S, Helmiö M, et al. Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss, comorbidities, and reflux at 10 years among patients with obesity: the SLEEVEPASS randomized clinical trial. JAMA Surg. 2022;157(8):656–666. https://doi.org/10.1001/jamasurg.2022.2229
5. Flum DR, Belle SH, King WC, et al; Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361(5):445–454. https://doi.org/10.1056/NEJMoa0901836
6. Sjöström L, Narbro K, Sjöström CD, et al; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–752. https://doi.org/10.1056/NEJMoa066254
7. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56–65. https://doi.org/10.1001/jama.2011.1914
8. Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297–2304. https://doi.org/10.1001/jama.2014.5988
9. Carlsson LMS, Sjöholm K, Jacobson P, et al. Life expectancy after bariatric surgery in the Swedish Obese Subjects study. N Engl J Med. 2020;383(16):1535–1543. https://doi.org/10.1056/NEJMoa2002449
10. Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2021;397(10271):293–304. https://doi.org/10.1016/S0140-6736(20)32649-0
11. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753–761. https://doi.org/10.1056/NEJMoa066603
12. Adams TD, Davidson LE, Litwin SE, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. 2017;377(12):1143–1155. https://doi.org/10.1056/NEJMoa1700459
13. Aminian A, Zajichek A, Arterburn DE, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA. 2019;322(13):1271–1282. https://doi.org/10.1001/jama.2019.14231
14. Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures — 2019 update. Surg Obes Relat Dis. 2020;16(2):175–247. https://doi.org/10.1016/j.soard.2019.10.025
15. King WC, Chen JY, Mitchell JE, et al. Prevalence of alcohol use disorders before and after bariatric surgery. JAMA. 2012;307(23):2516–2525. https://doi.org/10.1001/jama.2012.6147
16. Castaneda D, Popov VB, Wander P, et al. Risk of suicide and self-harm is increased after bariatric surgery — a systematic review and meta-analysis. Obes Surg. 2019;29(1):322–333. https://doi.org/10.1007/s11695-018-3493-4
17. Aminian A, Vidal J, Salminen P, et al. Late relapse of diabetes after bariatric surgery: not rare, but not a failure. Diabetes Care. 2020;43(3):534–540. https://doi.org/10.2337/dc19-1057
18. Clapp B, Ponce J, Corbett J, et al. American Society for Metabolic and Bariatric Surgery 2022 estimate of metabolic and bariatric procedures performed in the United States. Surg Obes Relat Dis. 2024;20(5):425–431. https://doi.org/10.1016/j.soard.2024.01.012
19. Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care. 2021;44(10):2438–2444. https://doi.org/10.2337/dci21-0034
20. van Veldhuisen SL, Gorter TM, van Woerden G, et al. Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2022;43(20):1955–1969. https://doi.org/10.1093/eurheartj/ehac071
21. Schiavon CA, Bersch-Ferreira AC, Santucci EV, et al. Effects of bariatric surgery in obese patients with hypertension: the GATEWAY randomized trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). Circulation. 2018;137(11):1132–1142. https://doi.org/10.1161/CIRCULATIONAHA.117.032130
22. Arrowaili A. Efficacy and safety of GLP-1 receptor agonists in the management of weight recurrence or suboptimal clinical response after undergoing metabolic bariatric surgeries: a meta-analysis. Obes Surg. 2025;35(5):1947–1960. https://doi.org/10.1007/s11695-025-07856-y
23. Rockey DC. Severe alcohol-related liver disease following bariatric surgery. Clin Obes. 2025;15(6):e70041. https://doi.org/10.1111/cob.70041
24. Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology. 2020;159(4):1290–1301. https://doi.org/10.1053/j.gastro.2020.06.006
25. Arnetorp I, Peltonen M, Sjöholm K, et al. Obstructive sleep apnea following bariatric surgery: 20-year outcomes from the Swedish Obese Subjects study. Obesity (Silver Spring). 2026;34(4):819–828. https://doi.org/10.1002/oby.70154
26. Karlsson J, Taft C, Rydén A, Sjöström L, Sullivan M. Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity: the SOS intervention study. Int J Obes (Lond). 2007;31(8):1248–1261. https://doi.org/10.1038/sj.ijo.0803573
27. Schiavon CA, Cavalcanti AB, Oliveira JD, et al. Randomized trial of effect of bariatric surgery on blood pressure after 5 years. J Am Coll Cardiol. 2024;83(6):637–648. https://doi.org/10.1016/j.jacc.2023.11.032
28. Pepino MY, Okunade AL, Eagon JC, Bartholow BD, Bucholz K, Klein S. Effect of Roux-en-Y gastric bypass surgery: converting 2 alcoholic drinks to 4. JAMA Surg. 2015;150(11):1096–1098. https://doi.org/10.1001/jamasurg.2015.1884
29. Hage K, Barajas-Gamboa JS, Romero-Velez G, et al. Revisional procedures after sleeve gastrectomy for weight recurrence or inadequate weight loss: an analysis of the MBSAQIP database. J Clin Med. 2023;12(18):5975. https://doi.org/10.3390/jcm12185975
30. Singhal R, Ludwig C, Rudge G, et al; GENEVA Collaborators. 30-day morbidity and mortality of bariatric surgery during the COVID-19 pandemic: a multinational cohort study of 7704 patients from 42 countries. Obes Surg. 2021;31(10):4272–4288. https://doi.org/10.1007/s11695-021-05493-9

HeartBuddi • Your heart. Own it.